Estrogen Receptor and Immune Checkpoint Inhibitors: New Partners in Lung Cancer?-Reference-Cited by-同舟云学术

Estrogen Receptor and Immune Checkpoint Inhibitors: New Partners in Lung Cancer?

Published:2023-08-07 Issue:19 Volume:29 Page:3832-3834
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:

Author:

Valencia Karmele¹²³⁴⁵^ORCID,Montuenga Luis M.¹²³⁵⁶^ORCID,Calvo Alfonso¹²³⁵⁶^ORCID

Affiliation:

1. 1Program in Solid Tumors, CIMA-University of Navarra, Pamplona, Spain.

2. 2Consorcio de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

3. 3Navarra Health Research Institute (IDISNA), Pamplona, Spain.

4. 4Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain.

5. 5Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain.

6. 6Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain.

Abstract

SummaryThe influence of sex on immunotherapy response in patients with non–small cell lung cancer (NSCLC) had been studied with no clear conclusions. An article in this issue reports that a key determinant of response is not sex but the existence of a 17β-estradiol/ERα/PDL1 signaling loop in NSCLC. This intriguing result opens new therapeutic options.See related article by Anobile et al., p. 3958

Funder

Centro de Investigación Biomédica en Red de Cáncer

Fundación Científica Asociación Española Contra el Cáncer

Gobierno de Navarra

Instituto de Salud Carlos III

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Link

https://aacrjournals.org/clincancerres/article-pdf/doi/10.1158/1078-0432.CCR-23-1736/3355020/ccr-23-1736.pdf

Reference17 articles.

1. Autocrine 17-β-estradiol/estrogen receptor-α loop determines the response to immune-checkpoint inhibitors in non–small cell lung cancer;Anobile;Clin Cancer Res,2023

2. Effect of gender on the outcome of patients receiving immune checkpoint inhibitors for advanced cancer: a systematic review and meta-analysis of phase III randomized clinical trials;Grassadonia;J Clin Med,2018

3. Cancer immunotherapy efficacy and patients’ sex: a systematic review and meta-analysis;Conforti;Lancet Oncol,2018

4. Association of patient sex with efficacy of immune checkpoint inhibitors and overall survival in advanced cancers: a systematic review and meta-analysis;Wallis;JAMA Oncol,2019

5. Gender and outcomes in non–small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?;Pinto;ESMO Open,2018